SOAM
DNLI icon

SBI Okasan Asset Management’s Denali Therapeutics DNLI Stock Holding History

SBI Okasan Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$764K Hold
29,500
– – 0.03% 167
2026
Q1 		$533K Buy
29,500
+11,500
+64% +$229K 0.02% 190
2025
Q4 		$298K Buy
+18,000
New +$304K 0.02% 217

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Okasan Asset Management's DNLI Position: Q2 2026 in Review

SBI Okasan Asset Management held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 29,500 shares worth $764K. The position accounts for 0.03% of the portfolio, ranked #167.

SBI Okasan Asset Management first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. 293 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • SBI Okasan Asset Management held 29,500 shares of Denali Therapeutics worth $764K as of Q2 2026.
  • SBI Okasan Asset Management left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up 0.03% of SBI Okasan Asset Management's portfolio in Q2 2026, its #167 holding.
  • SBI Okasan Asset Management first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 293 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.